Preliminary experience with mycophenolate mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity

Nephrology

Volumn 11, Issue 2, 2006, Pages 151-155

  Al Aly, Ziyad ^a   Sachdeva, Ashutosh ^a   Philoctete Ashley, Jennifer M ^a   Bastani, Bahar ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Azathioprine; Calcineurin inhibitors nephrotoxicity; Cardiac transplantation; Cyclosporine; Mycophenolate mofetil; Nephrotoxicity

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ARTICLE; CARDIAC GRAFT REJECTION; CARDIAC PATIENT; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPERIENCE; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HEMODIALYSIS; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; PRIORITY JOURNAL;

AGED; AZATHIOPRINE; CHRONIC DISEASE; CREATININE; CYCLOSPORINE; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 33645842225     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2006.00548.x     Document Type: Article

References (42)

1. Al Aly Z Abbas S Moore E Diallo O Hauptman PJ Bastani B. The natural history of renal function following orthotopic heart transplant. Clin. Transplant. 2005 19 683 9.
2. Myers BD Newton L. Cyclosporine-induced chronic nephropathy: An obliterative microvascular renal injury. J. Am. Soc. Nephrol. 1991 2 S45 52.
3. Myers BD Sibley R Newton L et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int. 1988 33 590 600.
4. Myers BD Ross J Newton L Luetscher J Perlroth M. Cyclosporine-associated chronic nephropathy. N. Engl. J. Med. 1984 311 699 705.
5. Myers BD Newton L Boshkos C et al. Chronic injury of human renal microvessels with low-dose cyclosporine therapy. Transplantation 1988 46 694 703.
6. Goldstein DJ Zuech N Sehgal V Weinberg AD Drusin R Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: Incidence and progression. Transplantation 1997 63 664 8.
7. Lindelow B Bergh CH Herlitz H Waagstein F. Predictors and evolution of renal function during 9 years following heart transplantation. J. Am. Soc. Nephrol. 2000 11 951 7.
8. Greenberg A Thompson ME Griffith BJ et al. Cyclosporine nephrotoxicity in cardiac allograft patients - a seven-year follow-up. Transplantation 1990 50 589 93.
9. Greenberg A Egel JW Thompson ME et al. Early and late forms of cyclosporine nephrotoxicity: Studies in cardiac transplant recipients. Am. J. Kidney Dis. 1987 9 12 22.
10. Bourge RC Naftel DC Costanzo-Nordin MR et al. Pretransplantation risk factors for death after heart transplantation: A multiinstitutional study. The Transplant Cardiologists Research Database Group. J. Heart Lung Transplant. 1993 12 549 62.
11. Radovancevic B Birovljev S Frazier OH et al. Long-term follow-up of cyclosporine-treated cardiac transplant recipients. Transplant. Proc. 1990 22 21 4.
12. Herlitz H Lindelow B. Renal failure following cardiac transplantation. Nephrol. Dial. Transplant. 2000 15 311 14.
13. Lewis RM Van Buren CT Radovancevic B et al. Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: Serial renal function in heart and kidney transplant recipients. J. Heart Lung Transplant. 1991 10 63 70.
14. Gonwa TA Mai ML Pilcher J et al. Stability of long-term renal function in heart transplant patients treated with induction therapy and low-dose cyclosporine. J. Heart Lung Transplant. 1992 11 926 8.
15. Zietse R Balk AH vd Dorpel MA Meeter K Bos E Weimar W. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am. J. Nephrol. 1994 14 1 5.
16. Tinawi M Miller L Bastani B. Renal function in cardiac transplant recipients: Retrospective analysis of 133 consecutive patients in a single center. Clin. Transplant. 1997 11 1 8.
17. Goral S Ynares C Shyr Y Yeoh TK Johnson HK. Long-term renal function in heart transplant recipients receiving cyclosporine therapy. J. Heart Lung Transplant. 1997 16 1106 12.
18. Sanchez V Delgado JF Morales JM et al. Chronic cyclosporine-induced nephrotoxicity in heart transplant patients: Long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant. Proc. 2004 36 2823 5.
19. Morozumi K Thiel G Gudat F Mihatsch MJ. Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in patients with renal allografts. Transplant. Proc. 1993 25 537 9.
20. Morozumi K Thiel G Albert FW Banfi G Gudat F Mihatsch MJ. Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in renal allografts. Clin. Nephrol. 1992 38 1 8.
21. Collins BS Davis CL Marsh CL McVicar JP Perkins JD Alpers CE. Reversible cyclosporine arteriolopathy. Transplantation 1992 54 732 4.
22. Bantle JP Paller MS Boudreau RJ Olivari MT Ferris TF. Long-term effects of cyclosporine on renal function in organ transplant recipients. J. Lab. Clin. Med. 1990 115 233 40.
23. Aleksic I Baryalei M Busch T et al. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 2000 69 1586 90.
24. Tedoriya T Keogh AM Kusano K et al. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil. J. Heart Lung Transplant. 2002 21 976 82.
25. Angermann CE Stork S Costard-Jackle A et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients - the IMPROVED multi-centre study. Eur. Heart J. 2004 25 1626 34.
26. Mihatsch MJ Thiel G Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant. Proc. 1988 20 759 71.
27. Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int. J. Clin. Pharmacol. Ther. 1996 34 515 19.
28. Franceschini N Alpers CE Bennett WM Andoh TF. Cyclosporine arteriolopathy: Effects of drug withdrawal. Am. J. Kidney Dis. 1998 32 247 53.
29. Shihab FS Andoh TF Tanner AM et al. Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. Kidney Int. 1996 49 1141 51.
30. Sharma VK Bologa RM Xu GP et al. Intragraft TGF-beta 1 mRNA: A correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int. 1996 49 1297 303.
31. Cuhaci B Kumar MS Bloom RD et al. Transforming growth factor-beta levels in human allograft chronic fibrosis correlate with rate of decline in renal function. Transplantation 1999 68 785 90.
32. Shihab FS Yamamoto T Nast CC et al. Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts. J. Am. Soc. Nephrol. 1995 6 286 94.
33. Pichler RH Franceschini N Young BA et al. Pathogenesis of cyclosporine nephropathy: Roles of angiotensin II and osteopontin. J. Am. Soc. Nephrol. 1995 6 1186 96.
34. Ziswiler R Steinmann-Niggli K Kappeler A Daniel C Marti HP. Mycophenolic acid: A new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J. Am. Soc. Nephrol. 1998 9 2055 66.
35. Hauser IAL Renders HH Radeke RB Sterzel M. Goppelt-Struebe, Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol. Dial. Transplant. 1999 14 58 63.
36. Badid C Vincent M McGregor B et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int. 2000 58 51 61.
37. Nadeau KC Azuma H Tilney NL. Sequential cytokine dynamics in chronic rejection of rat renal allografts: Roles for cytokines RANTES and MCP-1. Proc. Natl. Acad. Sci. USA 1995 92 8729 33.
38. Durez P Appelboom T Pira C Stordeur P Vray B Goldman M. Antiinflammatory properties of mycophenolate mofetil in murine endotoxemia: Inhibition of TNF-alpha and upregulation of IL-10 release. Int. J. Immunopharmacol. 1999 21 581 7.
39. Yang CW Ahn HJ Kim WY et al. Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity. Kidney Int. 2002 62 20 30.
40. Weir MR Anderson L Fink JC et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997 64 1706 10.
41. Hueso M Bover J Seron D et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998 66 1727 31.
42. Weir MR Ward MT Blahut SA et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int. 2001 59 1567 73.